Imperial Brands just wrapped a clinical trial that answers a question every manufacturer cares about: how fast does nicotine from your pouch actually hit the bloodstream, and how does that compare to competitors?

The study, listed in the ICH GCP clinical trials registry and updated February 2026, tested four unnamed oral nicotine products (labeled A, B, C, D) in 27 regular snus or pouch users. Each participant tried all four products over a four-day confinement period at a Swedish clinic, with researchers tracking pharmacokinetics — the science of how drugs move through your body.

What they measured

This was a randomized, cross-over, single-blind trial. "Cross-over" means each person used all four products in random order; "single-blind" means participants didn't know which product they were using at any given time.

Researchers tracked:

• Pharmacokinetic (PK) profiles: blood nicotine levels over time
• Nicotine extraction: how much nicotine actually left the pouch
• Subjective questionnaires: what users felt
• Safety and tolerability: side effects

The trial enrolled experienced users only — people who'd used snus or pouches for at least a year, went through a minimum of 2 cans weekly, and were comfortable with products containing 14-20 mg nicotine per pouch.

Why bioavailability matters for pouches

Bioavailability = the percentage of nicotine that reaches your bloodstream. A pouch might contain 10 mg of nicotine, but if only 30% gets absorbed, the effective dose is 3 mg. Delivery speed matters too: faster absorption can mean stronger satisfaction, which affects whether users stick with a product.

For manufacturers, this data helps optimize pouch design — pH levels, moisture content, pouch material all influence how nicotine transfers through the oral mucosa. For regulators, it's evidence for risk assessment: products with similar bioavailability to approved tobacco products might get easier regulatory paths in some markets.

What the trial didn't tell us

The registry listing doesn't include results — just that the study is complete. We don't know:

• Which products were tested (the "Product A/B/C/D" labels hide brand names)
• Which delivered nicotine fastest or most completely
• Whether participants preferred one over others
• Specific safety findings

The trial excluded anyone with significant medical history, pregnant or breastfeeding women, people with hepatitis B/C or HIV, those with substance abuse history, and anyone planning to quit nicotine in the next three months. That means findings apply to healthy, committed users — not casual experimenters or people trying to quit smoking.

The larger context

Imperial Brands (maker of Zone X and other pouch brands) isn't alone in running these studies. As nicotine pouches move toward mainstream regulation, manufacturers need clinical data to support market applications, especially in the US where the FDA requires premarket tobacco product applications (PMTAs) with pharmacokinetic evidence.

Sweden remains the go-to location for oral nicotine trials — it's one of the few markets with decades of snus use, making it easier to recruit experienced participants. The 27-person sample size is standard for early-stage bioavailability work, though larger trials typically follow if a product shows promise.

What's next: Imperial Brands hasn't published results publicly yet. If and when they do, expect the data to show up in regulatory filings or peer-reviewed journals — probably with the product names still anonymized unless they're seeking approval for a specific brand.

---

SOURCES:

• ICH GCP Clinical Trials Registry: https://ichgcp.net/clinical-trials-registry/NCT05452278